

ATRACURIUM

PRESENTATION:	Ampoules containing atracurium besilate 10mg/ml: 2.5ml, 5ml, 25ml.
INDICATION:	Muscle relaxation. Non-depolarising neuromuscular blocking agent with a medium duration of action.
DOSE AND ADMINISTRATION:	Atracurium is administered undiluted as a continuous infusion e.g. 500mg in a 50ml syringe. For example, for a 70kg patient the recommended rate is 4.5-5.5mls/hour (0.65-0.78mg/kg/hour), but rates up to 12mls/hour (1.77mg/kg/hour) may be needed. Use ideal body weight for obese patients.
CONCENTRATION:	10mg/ml
STABILITY:	Physically and chemically stable for 24hours
ADDITIONAL INFORMATION:	In common with all neuromuscular blocking agents, monitoring of neuromuscular function using train-of-four peripheral nerve stimulation is recommended during the use of atracurium in order to individualise dosage requirements.

References

1. Tracrium injection. Aspen. Summary of Product Characteristics.
<https://www.medicines.org.uk/emc/product/951/smpc> Accessed 17/06/20.
2. Atracurium besilate, Injectable Medicines Guide.
<https://medusa.wales.nhs.uk/IVGuideDisplay.asp?DrugNo=3733> Date published 18/04/20.
3. Ingrande J, Lemmens HJM. Dose adjustment of anaesthetics in the morbidly obese. British Journal of Anaesthesia, Volume 105, Issue suppl_1, December 2010.
4. British National Formulary. www.bnf.nice.org.uk Last updated 03/06/20.

Title: Atracurium	
ID:	Authors: Claire Hannah
Category:	Document Version: 2.0
Status Draft/Final: FINAL	Review Date: July 2022
Authoriser: Lothian Critical Care QIT Editorial Board	Authorisation Date: July 2020
Date added to Intranet:07/07/20	
Key Words	
Comments	

Critical Care Guidelines
FOR CRITICAL CARE USE ONLY